Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders

A method of treating a neurodegenerative disorder in a subject comprising administering to said subject in need of such treatment an effective amount of a compound having the formula:

• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• n is an integer from 0 to 3;
• X is selected from the group consisting of —S—, —O—, —NR— and CH2—;
• R1 and R2 are each independently selected from the group consisting of —H, —OR, —SR, —NRR, —NO2, CN, —C(O)OR, —C(O)NRR, —C(NR)NRR, trihalomethyl, halogen, (C1-C6) alkyl, substituted (C1-C6) alkyl, (C2-C6) alkenyl, substituted (C2-C6) alkenyl, (C2-C6) alkynyl, substituted (C2-C6) alkynyl, (C5-C20) aryl, substituted (C5-C20) aryl, 5-20 membered heteroaryl, substituted 5-20 membered heteroaryl, (C6-C26) alkaryl, substituted (C6-C26) alkaryl, 6-26 membered alk-heteroaryl and substituted 6-26 membered alk-heteroaryl,
• or R1 and R2 taken together are —CH2—(CH2)m—CH2—, where m is an integer from 0 to 6;
• each alkyl, alkenyl, alkynyl, aryl, alkaryl, heteroaryl or alk-heteroaryl substitutent is independently selected from the group consisting of —OR, —SR, —NRR, —CN, —NO2, —C(O)OR, —C(O)NRR, —C(S)NRR, —C(NR)NRR, halogen and trihalomethyl;
• and
• each R is independently selected from the group consisting of —H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C5-C20) aryl, 5-20 membered heteroaryl, (C6-C26) alkaryl and 6-26 membered alk-heteroaryl.